Refine by
Tissue Regeneration Articles & Analysis
37 news found
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
In the field of regenerative medicine and tissue engineering, the demand for collagen-based biomaterials is rapidly increasing. ...
Through this partnership, we aim to provide researchers with the tools and expertise needed to accelerate their research efforts in developing liver models for drug discovery, accurate cancer models for precision medicine, and exploring the potential of combining light and extrusion bioprinting modalities to advance tissue engineering.” Prof. Shaochen Chen added, ...
ByCELLINK
Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease. ...
It can precisely and accurately micron layered and gasify the skin lesions of acne scars, and the scar lesions can be removed intuitively. It can soften the diseased tissue with different characteristics of depth and shallowness without destroying the normal tissue. Through the regeneration of human skin tissue, the new skin is ...
SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications for shockwave systems in the non-medical field, announced today the patent activity for the full year 2020 and the first quarter of ...
SILKBridge® is an absorbable medical device made of Bombyx mori silk fibroin and is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. The tissue engineered technology at the core of SILKBridge® merges a deep-rooted cultural tradition and know-how with the most advanced technologies creating a ...
ByKLISBio
Monk will work closely with C-level management, research scientists, manufacturing, and our Quality and Regulatory team and services providers to mature NuShores’ bone and tissue regeneration product development efforts. NuShores is currently working on several new medical devices based on our pipeline of UALR licenses and internally developed innovations ...
Summarizing 20 years of both basic and clinical research, the review aims to provide a straightforward look at the current state of orthopedic regenerative cell therapies and clarifies the role of different regenerative cells, such as vaPS cells, in tissue regeneration. The publication highlights the advantages of InGeneron’s therapeutic approach utilizing ...
It is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect and is anticipated to be available for clinical use in 2023. ...
ByKLISBio
Investors keen to get involved with a company on the forefront of human tissue regeneration will be interested to visit with KLISBio, an international medtech company bringing its silk-based biomedical technology and the first of their products, SILKBridge®, to the Biotech Showcase Jan. 10-19. KLISBio is leading a revolution in restorative surgical ...
ByKLISBio
IPF is a chronic and ultimately fatal disease that causes lung tissue to stiffen, leading to permanent lung scarring that makes it harder to breathe. ...
This report demonstrates that the graft supports regeneration of the esophageal conduit. Histologic analysis of the tissue postmortem, 7.5 months after the implantation procedure, revealed complete luminal epithelialization and partial esophageal tissue regeneration." ...
The award recognizes his seminal and singular accomplishments in tissue regeneration, biomaterials science, nanotechnology, and regenerative engineering. ...
ByAlkermes
Low intensity shockwaves promote angiogenesis, increase nitric oxide release (NO), induces release of vascular endothelial growth factor (VEGF), stimulates reproduction of stem cells and effects tissue regeneration. Patented MoreNova applies low intensity shockwaves using patented applicators configured to deliver energy to anatomy of various shapes, i.e., ...
The Company’s team in Tokyo includes industry advisors CJ Partners, clinical research organization Accerise, Professor Akimichi Morita of Nagoya City University Hospital, and Professor Tsukasa Kumai of Waseda University all contributing to RepliCel’s clinical development and commercialization plans for its tissue regeneration cell therapy product ...
” “Implants that are bioinductive while providing structure for healing tissues during the repair or reconstruction continuum is the natural progression with this type of technology and I am looking forward to working with our surgeons to deliver the best-in-class implant for their practice and their patients,” commented Mr. ...
(OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, announced today that the Company has entered into a non-exclusive sales and marketing agreement with Ametus to market and sell the Company’s portfolio of wound care products in the ...
(NASDAQ:AMGN) and Rodeo Therapeutics Corporation (Rodeo) today announced an agreement under which Amgen will acquire Rodeo, a privately held biopharmaceutical company based in Seattle that develops small-molecule therapies designed to promote regeneration and repair of multiple tissues. Rodeo's 15-PGDH program is a strong strategic fit with Amgen's inflammation ...